Patents by Inventor J. Peter Klein

J. Peter Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds having selective hydrolytic potentials
    Patent number: 6780865
    Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
    Type: Grant
    Filed: September 18, 1997
    Date of Patent: August 24, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20040162288
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: November 13, 2003
    Publication date: August 19, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung
  • Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same
    Patent number: 6774130
    Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.
    Type: Grant
    Filed: April 9, 1999
    Date of Patent: August 10, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Stephen J. Klaus, Anil M. Kumar, Baoqing Gong
  • Hydroxyl-containing compounds
    Patent number: 6693105
    Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.
    Type: Grant
    Filed: July 27, 1999
    Date of Patent: February 17, 2004
    Assignee: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Pyridopyrimidine compounds and their uses
    Publication number: 20040023995
    Abstract: Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
    Type: Application
    Filed: May 18, 2001
    Publication date: February 5, 2004
    Inventors: Marc J. McKennon, J. Peter Klein, Michael Coon
  • Phospholipase D inhibitors and uses thereof
    Publication number: 20040002526
    Abstract: The invention is directed to thiazolidinones and the use thereof to inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones.
    Type: Application
    Filed: April 1, 2003
    Publication date: January 1, 2004
    Applicant: Cell Therapeutics, Inc.
    Inventors: J. Peter Klein, Anil M. Kumar, Marc J. McKennon
  • Manufacture of polyglutamate-therapeutic agent conjugates
    Publication number: 20030224971
    Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
    Type: Application
    Filed: April 2, 2003
    Publication date: December 4, 2003
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
  • Polyglutamic acid-camptothecin conjugates and methods of preparation
    Publication number: 20030216289
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 20, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Polyglutamic acid-camptothecin conjugates and methods of preparation
    Publication number: 20030211973
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: April 7, 2003
    Publication date: November 13, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Hydroxyl-containing compounds
    Publication number: 20030207901
    Abstract: Disclosed are therapeutic compounds having the formula:
    Type: Application
    Filed: May 14, 2003
    Publication date: November 6, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
  • Tricyclic compounds and their uses
    Publication number: 20030162801
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
    Type: Application
    Filed: January 24, 2003
    Publication date: August 28, 2003
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon
  • Aryl triazines as LPAAT-SS inhibitors and uses thereof
    Publication number: 20030153570
    Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.
    Type: Application
    Filed: October 30, 2002
    Publication date: August 14, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
  • Tricyclic fused xanthine compounds and their uses
    Patent number: 6586429
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling. The compounds have the following formulas where R1, R2 and R3 are defined in the written description of the invention.
    Type: Grant
    Filed: November 29, 2000
    Date of Patent: July 1, 2003
    Assignee: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20030100557
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: September 6, 2002
    Publication date: May 29, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Robert Finney, David Leung, J. Peter Klein, David M. Hollenback, Lynn Bonham, Scott A. Shaffer, Norina M. Tang, Thayer H. White, John Tulinsky, Baoqing Gong
  • Manufacture of polyglutamate-therapeutic agent conjugates
    Publication number: 20030054977
    Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.
    Type: Application
    Filed: July 18, 2002
    Publication date: March 20, 2003
    Applicant: Cell Therapeutics, Inc.
    Inventors: Anil Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
  • Polyglutamic acid-camptothecin conjugates and methods of preparation
    Publication number: 20020183243
    Abstract: The invention provides polyglutamic acid-therapeutic agent conjugates and methods for their preparation and use.
    Type: Application
    Filed: January 22, 2002
    Publication date: December 5, 2002
    Applicant: Cell Therapeutics, Inc.
    Inventors: Rama Bhatt, Peter de Vries, J. Peter Klein, John Tulinsky, Robert A. Lewis, Jack W. Singer
  • Method of inhibiting interleukin-12 signaling
    Patent number: 6469017
    Abstract: A method for blocking IL-12 signaling by administration of the following compound: wherein, R1 is H, CH3, sulfate, phosphate, or salt thereof; R2 is alkyl (C1-12), alkoxyalkyl (C1-11), dialkoxyalkyl, CH2C6H5, —CH2-furan, biotin; and R3 is H, CH3 or CH2C6H5.
    Type: Grant
    Filed: January 16, 1998
    Date of Patent: October 22, 2002
    Assignee: Cell Therapeutics, Inc.
    Inventors: Stephen J. Klaus, J. Peter Klein, Anil M. Kumar
  • Benzoxazole LPAAT-B inhibitors and uses thereof
    Publication number: 20020107269
    Abstract: The invention relates to benzoxazoles and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said benzoxazoles. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: October 31, 2001
    Publication date: August 8, 2002
    Applicant: CELL THERAPEUTICS, INC.
    Inventors: Lynn Bonham, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung
  • LPAAT-B inhibitors and uses thereof
    Publication number: 20020103195
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-&bgr; activity.
    Type: Application
    Filed: October 31, 2001
    Publication date: August 1, 2002
    Applicant: CELL THERAPEUTICS,INC.
    Inventors: Lynn Bonham, J. Peter Klein, Robert E. Finney, David M. Hollenback, Scott A. Shaffer, Norina M. Tang, Thayer H. White, David W. Leung
  • TRICYCLIC FUSED XANTHINE COMPOUNDS AND THEIR USES
    Publication number: 20020103211
    Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
    Type: Application
    Filed: November 29, 2000
    Publication date: August 1, 2002
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, J. Peter Klein, Michael Coon